Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis
Go back to Oruka Therapeutics Announces Positive Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Phase 2a Trial in Moderate-to-Severe Plaque Psoriasis| (NASDAQ: ORKA) | Delayed: 85.38 +13.04 (18.03%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $72.34 | 52 Week High | $ | |||
| Open | $81.00 | 52 Week Low | $ | |||
| Day High | $88.83 | P/E | N/A | |||
| Day Low | $79.00 | EPS | $ | |||
| Volume | 4,201,124 | |||||
